The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
A study of prescription of second line drugs in chronic tuberculosis patients before confirmation of multi drug resistance bacteriologically Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019